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due to breast cancer was possible among women with progressive disease, while death resulting from other causes was possible at any state. FISH was assumed to be a 'gold' standard for HER-2 status.
Outcomes assessed in the review
The outcomes assessed were the characteristics of HT compared with FISH, and the transition probabilities of the Markov model.
Study designs and other criteria for inclusion in the review
It was stated that most of the transition probabilities for the Markov model were derived primarily from a randomised clinical trial (RCT) . No further inclusion criteria for the studies were reported.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Only studies that compared HT with FISH used in accordance with the test manufacturers' instructions, on a series of unselected cases, and which reported results in adequate detail were included in the analysis.
Methods used to judge relevance and validity, and for extracting data
Not stated.
Number of primary studies included
Approximately 13 primary studies were included in the review.
Methods of combining primary studies
The results of individual primary studies were combined in the case of test characteristics for the identification of HER-2 overexpression. The average HT characteristics were calculated with each study's estimate weighted by the respective sample size of FISH+ and FISH-negative (FISH-) cases. Transition probabilities were verified by calibration with the end points of the RCT from which they were derived. The trial was simulated using a first-order Monte Carlo technique. The final transition probabilities used in the economic model were derived from the calibration model.
Investigation of differences between primary studies
Potential differences between the primary studies were not discussed further.
Results of the review
The probabilities of HT scores conditional on a FISH+ result were 0.079 for 0 and 1+ scores together, 0.250 for 2+ score, and 0.671 for 3+ score.
The probabilities of HT scores conditional on a FISH-result were 0.843 for 0 and 1+ scores together, 0.140 for 2+ score, and 0.017 for 3+ score.
The transition probabilities of the Markov model were as follows: the objective response rate for HER-2 positive cases was 54% for chemotherapy plus trastuzumab and 27% for chemotherapy alone;
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the monthly probability of disease progression for HER-2 negative cases was 12% in stable disease state and 9% in response state; the relative increase in progression rate for HER-2 positive cases receiving chemotherapy alone was 1.5%; the relative reduction in progression rate for HER-2 positive cases due to trastuzumab was 0.8%; the monthly probability of death as a result of progressive disease was 5%; and the prevalence of HER-2 positive disease was 25%.
Measure of benefits used in the economic analysis
The measure of benefit used was the number of quality-adjusted life-years (QALYs) gained from adopting each of the strategies examined. The utility weights for the base-case analysis were elicited from a sample of US oncology nurses. These utilities incorporated the impact of paclitaxel side effects on quality of life. It was assumed that the utility of each health state was equivalent for patients on chemotherapy plus trastuzumab and those on chemotherapy alone. An overview of breast cancer utility studies provided the utility weights used in the sensitivity analysis. The health benefits were estimated over the patients' lifetime and were discounted at an annual rate of 3%.
Direct costs
The direct costs included breast cancer-related medical costs and patient costs. Medical costs comprised the costs of HER-2 tests (HT or FISH), medication (trastuzumab and paclitaxel), premedication for paclitaxel, chemotherapy infusion, monitoring and/or treating side effects, oncologist visits, and treating progressive disease. Patient costs referred to the costs of travel for infusion visits and the time spent in treatment. The quantities and the unit costs were analysed separately for most of the cost elements considered in the analysis.
Some quantities, such as the number of oncologist visits, the travelling distance for infusion visits, and the monitoring tests required before and during treatment with trastuzumab, were based on authors' assumptions. HER-2 testing costs, cost of chemotherapy infusion, costs associated with monitoring and/or treating side effects, and oncologist visit unit costs were valued at their Medicare reimbursement amount. Medication costs were estimated using the Drug Topics Red Book and the Medicare Reimbursement Rates. Medicare relative value units, geographic practice components, and laboratory fees were obtained from the 2002 National Physician Fee Schedule and the 2002 Clinical Laboratory Fee Schedule. The costs of treating chemotherapy side effects and of treating progressive disease were derived from studies published in 1997 to 1998. The unit costs of travel were based on the standard mileage rate for calculating taxdeductible business travel. Patient time was valued using average annual earnings data collected in the Current Population Survey, 2002. Estimates of the quantity of time spent in treatment were not provided.
The total costs were derived using modelling. All the costs were expressed in 2002 values. Discounting was carried out at an annual rate of 3%, as the costs were incurred during the lifetime of the patients.
Statistical analysis of costs
The costs were treated deterministically. No statistical analysis of the costs was undertaken.
Indirect Costs
The indirect costs associated with the overall course of disease were not included in the analysis.
Currency

US dollars ($).
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Sensitivity analysis
A sensitivity analysis was undertaken to test the impact of variability in the parameter values on the results. All input parameters of the model were assessed in one-and two-way sensitivity analyses. The ranges for HT characteristics were derived from 95% confidence intervals of the weighted average values used in the base-case scenario. The ranges for the rest of the input parameters were derived from published literature and assumptions.
Estimated benefits used in the economic analysis
The QALYs gained per patient with each of the strategies were:
no initial test and chemotherapy alone for all patients, 1.28 QALYs;
HT alone and additional trastuzumab for HT 3+, 1.34 QALYs;
HT alone and additional trastuzumab for HT 2+ and 3+, 1.36 QALYs;
HT followed by FISH for HT 2+ and 3+ and additional trastuzumab for FISH+, 1.36 QALYs;
HT followed by FISH for HT 2+ and additional trastuzumab for HT 3+ and FISH+, 1.36 QALYs;
FISH alone and additional trastuzumab for FISH+, 1.37 QALYs; and no initial test and additional trastuzumab for all patients, 1.37 QALYs.
Cost results
The total costs per patient associated with each of the strategies were:
no initial test and chemotherapy alone for all patients, $43,314;
HT alone and additional trastuzumab for HT 3+, $51,231;
HT alone and additional trastuzumab for HT 2+ and 3+, $57,467;
HT followed by FISH for HT 2+ and 3+ and additional trastuzumab for FISH+, $53,702;
HT followed by FISH for HT 2+ and additional trastuzumab for HT 3+ and FISH+, $54,056; FISH alone and additional trastuzumab for FISH+, $54,738; and no initial test and additional trastuzumab for all patients, $79,181.
Synthesis of costs and benefits
The costs and benefits were combined in the form of incremental cost-effectiveness ratios (ICERs). The following strategies were dominated and excluded from further analysis:
HT alone and additional trastuzumab for HT 3+;
HT followed by FISH for HT 2+ and additional trastuzumab for HT 3+ and FISH+;
HT alone and additional trastuzumab for HT 2+ and 3+; and no initial test and additional trastuzumab for all patients.
Only two strategies were not ruled out by simple or extended dominance. Compared with no initial test and chemotherapy alone for all patients, HT followed by FISH for HT 2+ and 3+ and additional trastuzumab for FISH+ had
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In order to explore the effect of test characteristics on the outcomes, HT was replaced by a hypothetical IHC, the results of which were categorised as positive or negative. The testing strategies evaluated were no test, IHC alone, IHC with FISH confirmation of positive results (IHC+FISH), and FISH alone. Trastuzumab was given to patients found HER-2 positive. Two-way sensitivity analyses were undertaken. With an IHC specificity of 100%, the ICER of IHC compared with no test and chemotherapy alone was approximately $124,000/QALY as IHC sensitivity varied between 50 and 100%. The ICER of FISH alone increased from $129,000/QALY when IHC sensitivity was 50%, to more than $450,000/QALY when IHC sensitivity was 99%. At all values of IHC specificity, FISH alone was dominated if IHC sensitivity was 100%. IHC+FISH dominated IHC alone if IHC specificity was less than 99.6%, regardless of its sensitivity. Below this specificity threshold, the ICER of IHC+FISH remained relatively constant for varying values of IHC sensitivity. When IHC specificity was 60% and sensitivity was less than 70%, IHC+FISH was ruled out by extended dominance.
